
News|Videos|November 13, 2023
MARIPOSA-2: Amivantamab + Lazertinib + Chemotherapy in EGFR-Mutated Advanced NSCLC
Shared insight from key opinion leaders on results from MARIPOSA-2 and the role of amivantamab plus lazertinib and chemotherapy in patients with advanced NSCLC following progression on osimertinib.
Advertisement
Episodes in this series

Advertisement
Related Content




Divarasib Improves Survival Vs Approved KRAS G12C Inhibitors in NSCLC
Published: | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Advanced Renal Cell Carcinoma: Selecting Between IO/TKI and IO/IO Combination Therapy
2
After the First TKI Fails: Sequencing Challenges in ROS1-Positive NSCLC
3
Unique Benefits Seen With CAR T in AL Amyloidosis
4
CARTITUDE-4 Data, IMWG Guideline Make the Case for Second-Line CAR T in Myeloma
5

































